Traders assign a 90.5% implied probability to “No” on a new WHO-designated COVID-19 variant of concern before 2027 because SARS-CoV-2 continues evolving within established Omicron lineages without producing the major antigenic shifts or public-health impacts required for VOC status. As of late August 2026, the most recent VOC designation remains JN.1 from December 2023; current dominant or rising lineages such as NB.1.8.1, XFG, and BA.3.2 are tracked only as variants under monitoring, with WHO assessments rating global risk as moderate and noting limited additional immune escape or severity. Population-level hybrid immunity, updated 2025–2026 vaccines targeting JN.1 descendants, and sustained but non-escalating case trends have kept surveillance data stable. Any new VOC would require evidence of substantially altered transmissibility, virulence, or immune evasion not yet observed in ongoing genomic monitoring.